학술논문
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
Document Type
Academic Journal
Author
Reincke, S. Momsen; Yuan, Meng; Kornau, Hans-Christian; Corman, Victor M.; Hoof, Scott van; Sanchez-Sendin, Elisa; Ramberger, Melanie; Yu, Wenli; Hua, Yuanzi; Tien, Henry; Schmidt, Marie Luisa; Schwarz, Tatjana; Jeworowski, Lara Maria; Brandl, Sarah E.; Rasmussen, Helle Foverskov; Homeyer, Marie A.; Stoffler, Laura; Barner, Martin; Kunkel, Desiree; Huo, Shufan; Horler, Johannes; Wardenburg, Niels von; Kroidl, Inge; Wieser, Andreas; Geldmacher, Christof; Hoelscher, Michael; GSnzer, Hannes; Weiss, Gunter; Schmitz, Dietmar; Drosten, Christian; Wilson, Ian A.; Kreye, Jakob
Source
Science. February 18, 2022, Vol. 375 Issue 6582, p782, 6 p.
Subject
Language
English
ISSN
0036-8075
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type-elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.